MedTrace Logo

Hydroxypropyl-methylcellulose and GlicoPro® Eyedrops in the Treatment of Dry Eye Disease: Clinical Study

NCT06726525 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2024-12-10

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if Hydroxypropyl-methylcellulose and GlicoPro® eyedrops work to treat mild-to-moderate dry eye disease in adult patients. The main questions it aims to answer are:

Do Hydroxypropyl-methylcellulose and GlicoPro® eyedrops reduce patients' symptoms? Do Hydroxypropyl-methylcellulose and GlicoPro® eyedrops increase patients' tear film stability? Researchers will compare Hydroxypropyl-methylcellulose and GlicoPro® eyedrops to Hydroxypropyl-methylcellulose without GlicoPro® eyedrops to see if Hydroxypropyl-methylcellulose and GlicoPro® formulation works better to treat dry eye..

Participants will

* Take Hydroxypropyl-methylcellulose and GlicoPro® eyedrops or Hydroxypropyl-methylcellulose eyedrops every day for 3 months
* Visit the clinic 3 times in 3 months for checkups and tests

Conditions

  • Dry Eye

Interventions

DEVICE

HPMC+GlicoPro eyedrops

HPMC+GlicoPro eyedrops, artificial tears for dry eye disease

DEVICE

Hydroxypropyl-methylcellulose

Hydroxypropyl-methylcellulose eyedrops, artificial tears for dry eye disease

Sponsors & Collaborators

  • FB VISION, Ascoli Piceno, Italy

    collaborator UNKNOWN

  • University of Messina

    collaborator OTHER

  • University of Milan

    lead OTHER

Principal Investigators

  • Edoardo Villani, MD · University of Milan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-03
Primary Completion
2024-09-12
Completion
2024-09-12

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06726525 on ClinicalTrials.gov